Trial Profile

A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Acronyms PAZOGLIO

Most Recent Events

03 May 2024 Planned primary completion date changed from 1 Aug 2025 to 1 Feb 2027.
28 Feb 2024 The updated results (n=20) of the phase I presented at the ESMO Targeted Anticancer Therapies Congress 2024
28 Feb 2024 The phase II part is currently enrolling, according to results presented at the ESMO Targeted Anticancer Therapies Congress 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com